NCT00012467 is a Phase 2 clinical trial of Itraconazole in Meningitis, Cryptococcal, sponsored by InterMune.

Who is sponsoring NCT00012467?

NCT00012467 is sponsored by InterMune.

What drugs are being tested in NCT00012467?

Interventions in NCT00012467: Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b.

What condition does NCT00012467 study?

NCT00012467 studies Meningitis, Cryptococcal, HIV Infections.

Is NCT00012467 still recruiting?

NCT00012467 is currently completed. Last updated 29 May 2009.

Last reviewed 2009-05-29 · How we verify

NCT00012467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis

Completed Phase 2 Last updated 29 May 2009

What this trial tests

Phase 2 trial testing Itraconazole in Meningitis, Cryptococcal in 60 participants. Completed in 1 July 2001.

Timeline

1 January 2000

1 July 2001

Quick facts

Lead sponsor	InterMune
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 January 2000
Estimated completion	1 July 2001
Sites	9 locations across United States, Peru

Drugs / interventions tested

Itraconazole — full drug profile →
Flucytosine (FLUCYTOSINE) — full drug profile →
Fluconazole (fluconazole) — full drug profile →
Amphotericin B (AMPHOTERICIN B) — full drug profile →
Interferon gamma-1b

Conditions studied

Meningitis, Cryptococcal — all drugs for Meningitis, Cryptococcal →
HIV Infections — all drugs for HIV Infections →

Sponsor

InterMune — full company profile →

Who can join

13 and older, any sex, with Meningitis, Cryptococcal or HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Use of Interferon-gamma.
Miller CH, Maher SG, Young HA. · · 2009 · cited 244× · PMID 20074276 · DOI 10.1111/j.1749-6632.2009.05069.x
New Approaches for Cryptococcosis Treatment.
Spadari CC, Wirth F, Lopes LB, Ishida K. · · 2020 · cited 45× · PMID 32340403 · DOI 10.3390/microorganisms8040613
Cryptococcosis and Cryptococcal Meningitis: A Narrative Review and the Up-to-Date Management Approach.
Qureshi ZA, Ghazanfar H, Altaf F, Ghazanfar A, et al · · 2024 · cited 5× · PMID 38571832 · DOI 10.7759/cureus.55498
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.
Lu X, Zhou J, Ming Y, Wang Y, et al · · 2025 · cited 2× · PMID 40893690 · DOI 10.1016/j.apsb.2025.06.013

Verify or expand the search:

Other trials of Itraconazole

Trials testing the same drug.

NCT07341672 — A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itrac · Phase 1 · not yet recruiting
NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting
NCT07449390 — Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole · Phase 1 · not yet recruiting
NCT07435194 — A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazo · Phase 1 · recruiting
NCT07308652 — A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00012467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InterMune
Last refreshed: 29 May 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00012467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing